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Background: Cancer patients are at risk of thromboembolism. However, studies investigating the relationship
between ovarian cancer and ischemic stroke are lacking. The objectives of this study were to assess the association
between ovarian cancer and ischemic stroke, and to determine the predictive risk factors.
Methods: Ovarian cancer patients aged 20 years and older without antecedent cerebrovascular events and who
were followed up for more than 1 year between 1 January 2003 and 31 December 2011 were recruited from the
Taiwan National Health Insurance database. Hazard ratios (HRs) of stroke risk for ovarian cancer patients compared
with an age- and comorbidity-matched cohort were calculated by Cox proportional regression analysis. The
difference in cumulative ischemic stroke incidence between ovarian cancer patients and the matched cohort was
analyzed with the Kaplan-Meier method and tested with the log-rank test.
Results: Each cohort (ovarian cancer and matched cohort) consisted of 8,810 individuals, with a median age of
49 years. After a median follow-up of 2.68 and 3.85 years, respectively, the ischemic stroke incidence was 1.38-fold
higher in the ovarian cancer cohort than in the comparison cohort (9.4 versus 6.8 per 1,000 person-years), with an
age- and comorbidity-adjusted HR of 1.49 (P <0.001). The ischemic stroke risk imposed by ovarian cancer was more
prominent in patients under 50 years old (HR 2.28; P <0.001) compared with patients 50 years and older (HR 1.33;
P = 0.005). Significant risk factors predicting stroke development were age 50 years and older (HR 2.21; P <0.001),
hypertension (HR 1.84; P <0.001), diabetes mellitus (HR 1.71; P <0.001), and treatment with chemotherapy (HR 1.45;
P = 0.017), especially platinum-based regimens.
Conclusions: Ovarian cancer patients were at an increased risk of developing ischemic stroke. Age, hypertension,
diabetes, and chemotherapy treatment were independent risk factors.
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Ovarian cancer is the most common cause of cancer death
from gynecologic tumors and is an important global issue
requiring further attention [1]. Each year, more than 225,000
new ovarian cancers are diagnosed, and more than
140,000 deaths caused by ovarian cancer are estimated
to occur worldwide [2]. The introductions of surgical
cytoreduction, platinum-taxane-based chemotherapy,
and, most recently, intraperitoneal chemotherapy have* Correspondence: chiajenliu@gmail.com
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Consequently, the median survival for ovarian cancer
patients who undergo optimal surgery and adjuvant
chemotherapy can be as high as 60 to 110 months [3].
However, the occurrence of comorbidities, such as
cerebrovascular complications, after the cancer event may
exacerbate mortality in cancer survivors. In addition,
the median survival after stroke in cancer patients is
4.5 months, and treatment has no survival benefit [4]. In a
large autopsy series, up to 14.6% of cancer patients had
cerebrovascular complications [5]. Cancer and ischemic
stroke can cause heavy burdens on the economic and
healthcare systems and can disrupt the quality of life in
survivors. Therefore, it is very important to identifyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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provide them with close surveillance.
In ovarian cancer patients, there are a few studies and
reports mentioning the occurrence of stroke [6,7]. How-
ever, no large-scale study has examined the association
of ovarian cancer and ischemic stroke. Hence, it remains
unknown whether ovarian cancer patients exhibit an ele-
vated risk of developing ischemic stroke compared with
the general population. Therefore, a population-based
cohort study using the Taiwan National Health Insurance
(NHI) was conducted to examine this issue.
Methods
Data sources
Taiwan’s NHI program is a universal healthcare program
that was implemented in 1995. It currently covers more
than 99.5% of the entire population [8]. Data used in this
study were obtained from the research database of NHI,
which contains encrypted computerized medical claims,
inpatient and ambulatory care records, data from the
Registry for Catastrophic Illness Patients (RCIP), basic
demographic information, and other healthcare data. The
accuracy of diagnoses in this database has been validated
for several diseases, including ischemic stroke [9]. Diseases
were coded with the cancer International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
diagnosis codes, 2001 edition. Because the Taiwan NHI
research database contains encrypted computerized data
for research purposes, the ethics committee of Taipei
Veterans General Hospital informed us that this study
was exempt from full review and that informed consent
from each patient was not required.
Study subjects
Two cohorts, an ovarian cancer cohort and a matched con-
trol cohort, were enrolled in this study. The ovarian cancer
cohort (ICD-9-CM code 183.X) was identified from the
RCIP. For a patient to be enrolled in the RCIP, the diagnosis
of ovarian cancer had to be confirmed by histology. The
diagnosis was subject to periodic review by the Bureau of
NHI. Patients with a new ovarian cancer diagnosis made be-
tween 1 January 2003 and 31 December 2011 were included
in this study. Subjects younger than 20 years old, those who
had been diagnosed with any cerebrovascular disease before
ovarian cancer diagnosis, and those who were lost to
follow-up were excluded. Each individual in the ovarian
cancer group was matched on the basis of age, gender, time
of enrollment, and comorbidities related to cerebrovascular
events with an individual without ovarian cancer in a com-
parison cohort, which was also selected from the NHI.
Outcome measures
Occurrence of ischemic stroke was identified after the
initial diagnosis of ovarian cancer using medical claimsdata in the NHI. Ischemic stroke identification using data
in the Taiwan NHI is highly accurate compared to other
insurance databases and is valid for population-based re-
search [9]. In our study, identification was made on the
basis of ischemic stroke coding (ICD-9-CM code 436, 433.
X, 434.X, and 437.1X) accompanied by computed tomo-
graphic or magnetic resonance images. Diagnoses lacking
confirmatory image were not included. Subjects in both
cohorts (ovarian cancer and matched) were followed until
a diagnosis of ischemic stroke was made, death occurred,
31 December 2011 was reached, or the patient withdrew
from the NHI.
Statistical analyses
Microsoft SQL Server 2012 (Microsoft Corporation,
Redmond, WA, USA) and SAS 9.2 software (SAS Institute
Inc., Cary, NC, USA) were used for data management and
analysis. All statistical analyses were performed using SPSS
statistical software version 17.0 for Window (SPSS, Inc.,
Chicago, IL, USA). Statistical significance was defined
as a P value less than 0.05.
The demographic and clinical characteristics of ovarian
cancer patients and matched cohorts are presented as the
total number (n) and proportion (%). Continuous and cat-
egorical variables were compared between groups with the
Mann-Whitney U test and Pearson’s chi-squared test,
as appropriate. To assess the effect of age, study subjects
were divided into two subgroups: age <50 years and
age ≥50 years. Hazard ratio (HR) and 95% confidence inter-
vals (CI) were calculated with the Cox proportional hazard
models to test the association between ovarian cancer and
ischemic stroke; the HR was further adjusted for age and
comorbidities. The difference in the cumulative incidence
of ischemic stroke between the ovarian cancer patient
cohort and the matched cohort was calculated with the
Kaplan-Meier method and tested with the log-rank test.
Conventional risk factors for stroke, such as diabetes
mellitus and hypertension, which are also possible con-
founding factors, were further assessed for their effects on
the association of ovarian cancer and subsequent ischemic
stroke in univariate Cox proportion hazards models.
Additionally, therapeutic modalities, such as surgery
and chemotherapy, were put into Cox models as time-
dependent covariates to avoid immortal time bias. All
risk factors with P values <0.1 in the univariate model
were further entered into the multivariate analysis.
Results
Clinical characteristics of the study population
A total of 10,182 patients with ovarian cancer diagnosed
between 1 January 2003 and 31 December 2011 were
identified. Patients who were younger than 20 years old
(n = 277), diagnosed with cerebrovascular disease before
ovarian cancer diagnosis (n = 1,091), or lost to follow-up
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were included in the study (Figure 1). The demographic
characteristics of the study group and matched cohort
(1:1 ratio of patient number) are shown in Table 1.
All subjects in both groups were women with similar age
and comorbidity distributions. The median age was 49 years
for both cohorts (interquartile range (IQR), 41 to 58 years).
The most common comorbidity was hypertension (27.5%).
There was no difference in cerebrovascular event-related
comorbidities between the two groups. In the ovarian
cancer cohort, 6,160 patients (69.9%) received surgery,
and 6,590 patients (74.8%) received chemotherapy.
Incidence of ischemic stroke and risk factors
The median follow-up duration was 2.68 years (IQR, 1.44
to 4.98 years) for the ovarian cancer group and 3.85 years
(IQR, 1.83 to 6.14 years) for the matched cohort group.
During the follow-up period, there were 267 (9.4 per 1,000
person-years) new onset ischemic strokes in the study
cohort and 244 (6.8 per 1,000 person-years) in the matched
cohort. The incidence of ischemic stroke after the time
of enrollment increased with age in both cohorts. The
log-rank test showed a higher cumulative incidence of
ischemic stroke in the ovarian cancer group than in the
matched cohort (P <0.001) (Figure 2).
Compared with the matched cohort, the crude HR for
subsequent ischemic stroke after ovarian cancer was 1.38
(95% CI, 1.16 to 1.64; P <0.001). After adjusting for age
and comorbidities, the HR was 1.49 (95% CI, 1.25 to 1.78;
P <0.001). When the study subjects were stratified into
two subgroups, the relative risk (RR) of stroke was higher
(P <0.05) in subjects who were <50 years (adjusted HR
2.28; 95% CI, 1.55 to 3.36; P <0.001) compared with thoseFigure 1 Participant selection flow chart.who were ≥50 years old (adjusted HR 1.33; 95% CI, 1.09
to 1.62; P = 0.005) (Table 2).
In the multivariate Cox proportion hazards model, factors
independently determining the risk of subsequent ischemic
stroke in ovarian cancer patients included age ≥50 years
(HR 2.21; 95% CI, 1.64 to 2.99; P <0.001), diabetes mellitus
(HR 1.71; 95% CI, 1.27 to 2.29; P <0.001), hypertension
(HR 1.84; 95% CI, 1.39 to 2.43; P <0.001), and chemother-
apy treatment (HR 1.45; 95% CI, 1.07 to 1.97; P = 0.017)
(Table 3). Similarly, age ≥50 years, diabetes mellitus,
and hypertension were also independent risk factors for
ischemic stroke in the control cohort (Additional file 1:
Table S1). Comparing different chemotherapy modalities,
cisplatin-based (HR 1.38; 95% CI, 1.07 to 1.76; P = 0.012)
and carboplatin-based regimens (HR 1.46; 95% CI, 1.13
to 1.89; P = 0.004) were independent risk factors for subse-
quent ischemic stroke, whereas non-platinum-based regi-
mens (HR 1.12; 95% CI, 0.61 to 2.04; P = 0.722) were not.
These risk factors remained significant when 16 patients
who had a new diagnosis of brain metastasis (ICD-9-CM
code 198.3) less than three months after the stroke event
were censored for analysis, to avoid a short-term mis-
classification during acute brain insults (Additional file 1:
Table S2 and S3).
Discussion
This is the first population-based study to determine the
risk of new onset ischemic stroke after an ovarian cancer
diagnosis. Our data revealed an increased risk of developing
ischemic stroke with an adjusted HR of 1.49 among pa-
tients with ovarian cancer. Significant risk factors for is-
chemic stroke included age ≥50 years, diabetes mellitus,
hypertension, and chemotherapy treatment.
Table 1 Baseline patient characteristics of subjects with and without ovarian cancer
Demographic data Subjects with ovarian cancer Subjects without ovarian cancer P
n = 8,810 n = 8,810
n % n %
Age (interquartile range) 49 (41 to 58) 49 (41 to 58) 1.000
≥50 years 4,357 49.5 4,357 49.5 1.000
<50 years 4,453 50.5 4,453 50.5
Comorbidities
Diabetes mellitus 1,446 16.4 1,447 16.4 0.984
Hypertension 2,425 27.5 2,426 27.5 0.987
Chronic kidney disease 709 8.0 708 8.0 0.978
Dyslipidemia 1,987 22.6 1,986 22.5 0.986
Coronary artery disease 52 0.6 50 0.6 0.843
Atrial fibrillation 47 0.5 45 0.5 0.834
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lated, possibly induced by the underlying malignancy [10].
For cancer patients, RRs of developing venous thrombosis
of four- to seven-fold have been reported compared with
matched controls [11]. However, cancer is a broad disease
and different types of cancer may have different risks.
Generally, pancreas, brain, lung, and ovarian cancers have
been associated with the higher risks of developing venous
thrombosis [12]. In addition, the presence of disseminated
intravascular coagulation in patients with ovarian cancerFigure 2 Cumulative incidence of ischemic stroke in subjects with anmay indicate a hypercoagulative status [13]. One direct
evidence for the hypercoagulative state is the frequently
overexpressed tissue factor in ovarian cancer tissue, which
could activate the extrinsic coagulation cascade and cause
thrombolic events in ovarian cancer patients [14].
Although the temporal-causal relationship between ovar-
ian cancer progression and hypercoagulation is unknown,
high levels of coagulation factors and associated regulatory
proteins have been observed in ovarian cancer patients
[15,16]. Increased levels of circulating mucinous materiald without ovarian cancer.
Table 2 Incidence of ischemic stroke in subjects with and without ovarian cancer













Total 267 9.4 244 6.8 1.38 (1.16 to 1.64) <0.001 1.49 (1.25 to 1.78) <0.001
Age
≥50 years 192 15.5 205 12.1 1.29 (1.06 to 1.57) 0.012 1.33 (1.09 to 1.62) 0.005
<50 years 75 4.7 39 2.1 2.27 (1.54 to 3.34) <0.001 2.28 (1.55 to 3.36) <0.001
aAdjusted for age, sex, and comorbidities. CI, confidence interval; HR, hazard ratio.
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cular hypercoagulation and hyperviscosity [17]. Together,
these findings suggest that a subgroup of ovarian cancer
patients may have distinct coagulopathies, making these
patients vulnerable for specific vascular events, including is-
chemic stroke. These findings may also explain why ovarian
cancer survivors in our study, especially younger patients
who had no established conventional stroke risk factors,
possessed a higher risk of subsequent ischemic stroke.
The most well-known and medically important (that is,
treatable) risk factors for ischemic stroke include hyperten-
sion, diabetes mellitus, dyslipidemia, smoking, and obesity
[18]. Although lifestyle and obesity were not included
in the present analysis, some epidemiological studies
have demonstrated that hypertension and diabetes are
significant risk factors for stroke in several cancers [19,20].
Our multivariate analyses revealed a similar result, with
additional significant risk factors, including age ≥50 years
old and chemotherapy treatment. These results suggestTable 3 Analyses of risk factors for ischemic stroke in patient
Predictive variables Univariate
HR (95% CI)
Age ≥50 3.25 (2.49 to 4.25)
Comorbidities
Diabetes mellitus 2.84 (2.19 to 3.67)
Hypertension 3.15 (2.47 to 4.00)
Chronic kidney disease 1.64 (1.12 to 2.39)
Dyslipidemia 2.25 (1.75 to 2.89)
Coronary artery disease 3.66 (1.36 to 9.83)
Atrial fibrillation 0.75 (0.11 to 5.31)
Peripheral arterial occlusive disease 3.09 (0.43 to 22.02)
Treatmentb
Surgeryc 0.83 (0.64 to 1.06)
Chemotherapy 1.67 (1.25 to 2.25)
Cisplatin-based 1.35 (1.06 to 1.73)
Carboplatin-based 1.76 (1.37 to 2.25)
Non-platinum-based 1.24 (0.68 to 2.26)
aAll factors with P <0.1 in univariate analyses were included in the Cox multivariate
regression model; csurgery included unilateral or bilateral salpingo-oophorectomy, othat conventional stroke risk factors remain important in
the pathogenesis of stroke in ovarian cancer patients.
Our study showed that ovarian cancer patients receiving
chemotherapy, particularly platinum-based regimens, might
have an additionally increased stroke risk. This effect
was insignificant in non-platinum-based regimens. In
prior studies, chemotherapy-associated increased stroke
was observed in patients with head-and-neck cancer
[19,21], breast cancer [22], and urothelial carcinoma [23].
While the mechanism is still uncertain, some suggested
pathophysiologies are associated with increased fibrino-
peptide A and decreased fibrinolytic activity [24], elevated
plasma von Willebrand factor [25], hypomagnesium-
associated vascular spasm [26,27], endothelial injury
[28,29], and mononuclear cell-mediated platelet activation
[30]. Moreover, Li et al. demonstrated that platinum in
a chemotherapy regimen, which is also commonly used
for treating ovarian cancer patients, may increase the risk
of ischemic stroke among cancer patients [31]. Cerebrals with ovarian cancer
analysis Multivariate analysisa
P HR (95% CI) P
<0.001 2.21(1.64 to 2.99) <0.001
<0.001 1.71(1.27 to 2.29) <0.001
<0.001 1.84(1.39 to 2.43) <0.001
0.011 1.05(0.71 to 1.56) 0.791
<0.001 1.09(0.81 to 1.46) 0.569




0.001 1.45(1.07 to 1.97) 0.017
0.017 1.38(1.07 to 1.76) 0.012
<0.001 1.46(1.13 to 1.89) 0.004
0.490 1.12(0.61 to 2.04) 0.722
analysis; btreatment was analyzed as a time-dependent covariate in the Cox
r debulking surgery. CI, confidence interval; HR, hazard ratio.
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cancer patients has also been reported previously [32,33].
A meta-analysis of 38 randomized phase II and III trials
showed that cancer patients who received cisplatin-based
chemotherapy demonstrated a dose-dependently increased
risk (RR 1.67, 95% CI, 1.25 to 2.23; P = 0.01) of thrombo-
embolism compared with patients who received a non-
cisplatin-based regimen [34]. More research is needed to
clarify the role of chemotherapy in the relationship of
ovarian cancer and subsequent ischemic stroke, as well
as to determine whether it is necessary to use a prophy-
lactic antiplatelet agent in high-risk patients during the
chemotherapy period.
Our study revealed that ovarian cancer patients appeared
to have a higher risk of stroke soon after cancer diagnosis,
and the increased risk persisted throughout the follow-up
period. A similar phenomenon was also observed in sur-
vivors of head-and-neck cancer [19,21], cervical cancer
[35], breast cancer [36], and Hodgkin lymphoma [37].
The stroke risk imposed by ovarian cancer seemed to be
more prominent in people of younger age, with adjusted
HRs of 2.28 and 1.33 in the age groups of <50 years
and ≥50 years, respectively. These findings suggest that,
with increasing age, the age factor becomes more important
than cancer as a risk factor of stroke.
This study has several limitations. First, lifestyle vari-
ables and behavioral factors, such as tobacco and alcohol
use, body mass index, dietary habits, and biochemistry
profiles including serum D-dimer level and disseminated
intravascular coagulation profiles, were not available in the
claims data of the Taiwan NHI. Second, cancer staging and
histology were not available in this database, and their
association with ischemic stroke could not be identified.
Finally, information on the cause of death was not available;
consequently, we cannot determine the impact of stroke
on cancer-related mortality. Despite these limitations, our
study was based on a nationwide, population-based
database that could identify all cases of ovarian cancer and
ischemic stroke in the study period. The large sample size
in our study contributed to substantial statistical power and
revealed a clear association between ovarian cancer and is-
chemic stroke, with subtle statistically significant differences
between the two cohorts.
Conclusions
This nationwide population-based study demonstrated
that ovarian cancer patients are at an increased risk of
subsequent ischemic stroke. Significant risk factors in-
cluded age ≥50 years, hypertension, diabetes mellitus,
and chemotherapy treatment, especially platinum-based
regimens, following a diagnosis of ovarian cancer. With
the longer expected life span of ovarian cancer patients,
close surveillance and proper stroke-prevention strategies
may be needed. Further prospective clinical studies of therelationship between ovarian cancer and ischemic stroke
are warranted.
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